UPXI,COEP Stock Price and Quote

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change -2.59
Percentage change -16.70	%

Peers: FUTU CNF JFIN NISN OCFT JFU BTBT SOS UOKA STCN

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-23.29	Insider Own	22.11%	Shs Outstand	1.05M	Perf Week	30.64%
Market Cap	17.07M	Forward P/E	-	EPS next Y	-	Insider Trans	322.84%	Shs Float	1.03M	Perf Month	447.46%
Income	-23.65M	PEG	-	EPS next Q	-	Inst Own	1.18%	Short Float	5.92%	Perf Quarter	219.01%
Sales	81.43M	P/S	0.21	EPS this Y	-	Inst Trans	0.77%	Short Ratio	0.03	Perf Half Y	271.26%
Book/sh	3.60	P/B	3.59	EPS next Y	-	ROA	-33.03%	Short Interest	0.06M	Perf Year	28.43%
Cash/sh	0.31	P/C	41.63	EPS next 5Y	-	ROE	-72.85%	52W Range	1.90 - 22.57	Perf YTD	268.08%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-96.18%	ROI	-342.18%	52W High	-42.76%	Beta	-1.03
Dividend TTM	-	Quick Ratio	0.36	Sales past 5Y	97.17%	Gross Margin	26.62%	52W Low	579.64%	ATR (14)	2.88
Dividend Ex-Date	-	Current Ratio	0.58	EPS Y/Y TTM	-362.93%	Oper. Margin	-9.71%	RSI (14)	73.95	Volatility	44.83% 27.06%
Employees	64	Debt/Eq	2.80	Sales Y/Y TTM	4.32%	Profit Margin	-29.04%	Recom	3.00	Target Price	25.00
Option/Short	No / No	LT Debt/Eq	0.84	EPS Q/Q	27.46%	Payout	-	Rel Volume	0.99	Prev Close	15.51
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-85.35%	Earnings	-	Avg Volume	2.13M	Price	12.92
SMA20	147.25%	SMA50	241.88%	SMA200	189.28%	Trades		Volume	2,098,764	Change	-16.70%

Apr-24-25 04:10PM	Upexi Announces Closing of $100 Million Private Placement (ACCESSWIRE) +22.80% +14.72%
Apr-22-25 09:51AM	Why Upexi, Inc. (UPXI) Soared on Monday (Insider Monkey) -9.00%
Apr-21-25 11:22AM	Solana Pushes Higher As Staking Milestone And Institutional Bets Fuel Rally (Benzinga) +330.94%
11:09AM	GSR Anchors $100M Investment in Upexi to Purchase SOL, Stock Rockets 700% (CoinDesk)
08:00AM	Upexi Announces Pricing of $100 Million Private Placement Priced Above Last Market Closing Price under Nasdaq Rules (ACCESSWIRE)
08:00AM	Loading…
Feb-06-25 08:00AM	Upexi Provides Shareholder Update on Current Business Operations and Long-Term Strategic Crypto Portfolio and Mining Initiative (ACCESS Newswire) +6.22%
Jan-24-25 08:00AM	Upexi Appoints Industry Expert, James Altucher, as Advisor to Guide Strategic Digital Treasury Portfolio Management (ACCESSWIRE)
Jan-23-25 08:00AM	Upexi Shifts Focus into Bitcoin and Crypto with Strategic Investment in Digital Currency as Part of Long-Term Strategic Crypto Initiative (ACCESSWIRE) +24.63%
Dec-23-24 09:00AM	Upexi Regains Compliance with NASDAQ (ACCESSWIRE) -10.63%
Nov-25-24 08:00AM	Upexi Files litigation in Nevada as first Step in Determining Manipulation of Fractional Share Roundups during Reverse Stock Split (ACCESSWIRE) -10.11%
Nov-22-24 09:00AM	Upexi Recieves Notice from The Nasdaq Stock Market (ACCESSWIRE) +8.25%
Oct-25-24 08:30AM	Upexi to Take Action Against Apparent Stock Manipulation of Fractional Share Roundup with Reverse Stock Split (ACCESSWIRE) +170.00%
Oct-23-24 08:00AM	Upexi to File Form 10-K on November 1st and Regains Compliance with Nasdaq Minimum Bid Price Rule (ACCESSWIRE) -15.33%
Aug-05-24 08:00AM	Upexi Provides Shareholder Update on Restructuring to Reduce Debt and Increase Working Capital (ACCESSWIRE)
Jul-09-24 12:52PM	UPXI Stock Earnings: Upexi Misses EPS, Misses Revenue for Q3 2024 (InvestorPlace)
08:00AM	Loading…
08:00AM	Upexi Reports Fiscal Third Quarter 2024 Financial Results (ACCESSWIRE)
Jul-03-24 07:21AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -9.58%
Jun-21-24 04:30PM	Upexi Provides Update on Filing Form 10Q for March 31, 2024 (ACCESSWIRE) +7.76%
Jun-20-24 09:00AM	Upexi Provides Shareholders with Update on Restructuring to Reduce Debt and Increase Working Capital through Sale of Assets (ACCESSWIRE)
Jun-06-24 09:00AM	Upexi Completes Consolidation of Operations and Announces Initiating Process to Explore Strategic Alternatives to Enhance Shareholder Value (ACCESSWIRE)
May-01-24 07:31AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -6.98%
Mar-20-24 08:00AM	Upexi's Tytan Tile Kits, Disney Frozen and New Disney JR Mikey Mouse Set, will Soon be Available in BJ's Wholesale Club (ACCESSWIRE)
Mar-07-24 09:00AM	Upexi's Children Educational Toy Brand, Tytan Tiles, Disney Frozen Tile Kit will be Available in TJ Maxx Stores (ACCESSWIRE)
Feb-15-24 09:49AM	Upexi, Inc. (NASDAQ:UPXI) Q2 2024 Earnings Call Transcript (Insider Monkey) -29.71%
05:37AM	Q2 2024 Upexi Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-14-24 04:05PM	Upexi Reports Fiscal Second Quarter 2024 Financial Results (ACCESSWIRE) +6.98%
Feb-12-24 09:00AM	Upexi to Host Fiscal 2024 Second Quarter Financial Results Conference Call on February 14th at 4:30 PM ET (ACCESSWIRE)
Jan-31-24 08:30AM	Upexi Leading Toy Brand, Tytan Toys, Strengthens Global Presence with Expansion into Pricesmart (ACCESSWIRE)
Jan-04-24 11:00AM	Upexi CEO, Allan Marshall, to Present at the iAccess Alpha 2024 Buyside Best Ideas Summit on January 9th & 10th (ACCESSWIRE)
09:30AM	iAccess Alpha Tax Loss Recovery Summit 2024 - Buyside Best Ideas January 9th-10th 2024 (ACCESSWIRE)
08:30AM	Loading…
Nov-28-23 08:30AM	Upexi's Tytan Tiles Toy Brand Launches on Walmart.com after Becoming Top Seller on Amazon (ACCESSWIRE) -8.31%
Nov-24-23 09:12AM	Upexi, Inc. (NASDAQ:UPXI) Q1 2024 Earnings Call Transcript (Insider Monkey)
Nov-20-23 04:05PM	Upexi Revenue Increases 144% Year-Over-Year and 53.5% Sequentially to $27.3 Million for Fiscal First Quarter 2024 (ACCESSWIRE) -9.09%
Nov-14-23 09:00AM	Upexi Preannounces Revenue of $27.3 Million for Fiscal 2024 First Quarter and Reschedules Financial Results Conference Call for November 20th at 4:30 PM ET (ACCESSWIRE)
Nov-03-23 08:30AM	Upexi to Host Fiscal 2024 First Quarter Financial Results Conference Call on November 14th at 4:30 PM ET (ACCESSWIRE) +8.94%
Oct-17-23 08:30AM	Upexi's Children Toy Brand, Tytan Tiles, Launches Licensed Disney Frozen Product on Amazon (ACCESSWIRE)
Oct-02-23 04:01PM	Upexi Fiscal 2023 Revenue Increases 250% Year-Over-Year to $80.7 Million and Provides Revenue Guidance Range for Fiscal 2023 First Quarter (ACCESSWIRE) -9.88%
Sep-28-23 04:15PM	Upexi to Host Fiscal 2023 Full Year Financial Results Conference Call on October 2nd at 4:30 PM ET (ACCESSWIRE)
08:30AM	Upexi CEO, Allan Marshall, to Participate in Fireside Chat at the Jefferies Pet Care and Wellness Summit (ACCESSWIRE)
Sep-14-23 08:30AM	Upexis Pet Care Brand, LuckyTail, Announces Expansion of Product Line to Include All-Natural Dog Supplements (ACCESSWIRE)
Sep-06-23 09:00AM	Upexi Announces Strategic Operational Measures to Monetize Non-Core Assets, Reduce Expenses and Drive Profitability (ACCESSWIRE)
Aug-17-23 08:00AM	Upexi Provides Corporate Update (ACCESSWIRE) -7.47%
Jul-27-23 08:00AM	Upexi Implements Re:Amaze Artificial Intelligence (AI) Tool to Enhance Online Experience for its Customers (ACCESSWIRE)
Jul-10-23 06:56AM	Daily Vickers Top Buyers & Sellers for 07/10/2023 (Argus Research)
Jun-20-23 09:45AM	Upexi Voluntarily Terminates Acquisition of Superfoods Brand (ACCESSWIRE)
Jun-16-23 09:40AM	Upexi Announces Fireside Chat Hosted by Alliance Global Partners on June 21st at 10 AM ET (ACCESSWIRE)
Jun-14-23 03:00PM	Upexis Tytan Tiles Brand Featured on Good Morning America (ACCESSWIRE)
Jun-08-23 08:00AM	Upexis Toy Brand, Tytan Magnetic Tiles, Announces New First Party Agreement with Amazon.com for Launch and Expansion of Disney Products (ACCESSWIRE) -5.67%
06:06AM	Investors Don't See Light At End Of Upexi, Inc.'s (NASDAQ:UPXI) Tunnel And Push Stock Down 29% (Simply Wall St.)
May-24-23 09:15AM	Upexi Initiates Development of Artificial Intelligence (AI) Engine to Optimize Future Advertising, Marketing and Logistics Decisions (ACCESSWIRE)
May-15-23 04:05PM	Upexi Reports Revenue of $24.2 Million for Fiscal 2023 Third Quarter, an Increase of 447% Year-Over-Year (ACCESSWIRE) +5.10% -9.16%
11:16AM	Insider Buyers Lose Additional US$29k As Upexi Dips To US$63m \ (Simply Wall St.)
May-12-23 08:30AM	Upexi, Inc. Announces $7 Million Registered Direct Offering of Common Stock (ACCESSWIRE) -18.66%
May-09-23 09:00AM	Upexi to Host Fiscal 2023 Third Quarter Financial Results on May 15th at 4:30 PM ET (ACCESSWIRE)
May-08-23 08:30AM	Upexi's Tytan Tiles Toy Brand Announces Licensing Agreement with The Walt Disney Company and its Brands Including Frozen and Toy Story (ACCESSWIRE)
Apr-18-23 02:06PM	Upexi Streamlines Third Party Logistics Locations To Cut Costs By $1M-$1.5M (Benzinga)
08:30AM	Upexi to Improve Operating Efficiencies and Reduce Distribution Costs by $1 to $1.5 Million by Consolidating Third Party Logistics Locations (ACCESSWIRE)
Apr-13-23 08:30AM	Upexi Signs Letter of Intent to Acquire Wellness and Nutrition Brand with Trailing Twelve Month Revenue of $15 Million and Positive EBITDA (ACCESSWIRE)
Apr-12-23 12:13PM	Upexi Takes Full Control Of Amazon-Reseller Cygnet Online One-Year Ahead Of Schedule (Benzinga) +6.41%
08:30AM	Upexi Agrees to Acquire Remaining 45% Interest in Cygnet Online One Year Ahead of Schedule (ACCESSWIRE)
Mar-02-23 08:30AM	Upexi to Present at the 35th Annual Roth Conference (PR Newswire)
Feb-23-23 08:30AM	Upexi's Tytan Tiles Brand Expands Initial Launch of 2,200 Walmart Locations to Over 3,900 Locations for Second Half of 2023 (PR Newswire)
Feb-16-23 05:06AM	Upexi Second Quarter 2023 Earnings: EPS: US$0.17 (vs US$0.004 in 2Q 2022) (Simply Wall St.)
Feb-14-23 04:05PM	Upexi Reports Record Revenue of $27.1 Million for Fiscal 2023 Second Quarter, an Increase of 444% Year-Over-Year (PR Newswire) +6.76% +11.39%
Feb-07-23 08:30AM	Upexi to Host Fiscal 2023 Second Quarter Financial Results on February 14th at 5:00 PM ET (PR Newswire) +11.52%
Jan-27-23 06:07AM	Upexi (NASDAQ:UPXI) shareholders have endured a 24% loss from investing in the stock a year ago (Simply Wall St.)
Jan-18-23 09:00AM	Upexi's Tytan Tiles Brand, a Top Selling Toy on Walmart.com, Launches Branded Amazon Storefront (PR Newswire)
Jan-12-23 06:50AM	Daily Vickers Top Buyers & Sellers for 01/12/2023 (Argus Research) +9.04%
Dec-14-22 09:20AM	Upexi Announces Record Quarter-to-Date Retail and DTC Gross Revenue of Approximately $19 Million Gross and $17 Million Net of Discontinued Operations (PR Newswire)
Dec-01-22 08:30AM	Upexi CEO, Allan Marshall, to Participate in Fireside Chat at the Wolfe Research Fall Global Consumer Conference on December 5th (PR Newswire) +12.69%
Nov-29-22 08:30AM	Upexi's Toy Brand, Tytan Tiles, to Launch in 2,000 Walmart Retail Stores in January (PR Newswire) -6.54%
Nov-14-22 04:05PM	Upexi Revenue Increases 199% Year-Over-Year to $11.6 Million for Fiscal 2023 First Quarter (PR Newswire) -7.59% -5.89%
Nov-03-22 08:00AM	Upexi Eliminates Outstanding Balance of $15 Million Senior Secured Debt and Plans to Terminate Underlying Registration Statement (PR Newswire) +6.67%
Nov-02-22 08:30AM	Upexi Closes Acquisition of E-Core and its Subsidiaries, Adding Over $40 Million in Trailing Twelve Month Sales and Increasing Projected Calendar 2023 Sales to $100M (PR Newswire)
Oct-31-22 08:30AM	Upexi to Host Fiscal 2023 First Quarter Financial Results on November 14th at 4:30 PM ET (PR Newswire)
Oct-27-22 08:31AM	Bloomios Completes $23.5 Million Acquisition of Leading Gummy Manufacturer (PR Newswire)
08:30AM	Upexi Announces Sale of Select CBD Assets for $23.5 Million (PR Newswire)
Oct-11-22 08:30AM	Upexi's Ad Tech Division, Interactive Offers, Files New Patent (PR Newswire) -5.28%
Oct-01-22 08:35AM	A Upexi, Inc. (NASDAQ:UPXI) insider increased their holdings by 5.3% last year (Simply Wall St.)
Sep-29-22 10:29AM	Upexi Revenue Increases 85% Year-Over-Year to $44.6 Million for Fiscal 2022 (PR Newswire)
Sep-12-22 01:14PM	Unrivaled Brands Appoints Patty Chan as Interim Chief Financial Officer (GlobeNewswire)

Upexi, Inc. engages in the development, manufacturing, and distribution of consumer products through direct-to-consumer network, wholesale partnerships, and major third-party platforms like Amazon. Its brands include LuckyTail, Prax, Cure Mushrooms, Moonwlkr, and Gumi Labs. The company was founded on September 5, 2018 and is headquartered in Tampa, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MARSHALL ALLAN	Chief Executive Officer	Apr 17 '25	Buy	2.28	657,895	1,500,001	809,318	Apr 25 04:01 PM
Norstrud Andrew James	Chief Financial Officer	Apr 17 '25	Buy	2.28	43,860	100,001	59,138	Apr 25 04:01 PM
Salkind Gene	Director	Apr 17 '25	Buy	2.28	241,229	550,002	365,127	Apr 25 04:01 PM

Dollar change +1.27
Percentage change 16.49	%

COEP Coeptis Therapeutics Holdings Inc daily Stock Chart

Peers: GILD REGN PFE MRNA BNTX JNJ VRTX AZN AMGN LLY

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-5.65	Insider Own	14.11%	Shs Outstand	3.36M	Perf Week	-19.87%
Market Cap	30.64M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.93M	Perf Month	-3.65%
Income	-10.88M	PEG	-	EPS next Q	-	Inst Own	0.32%	Short Float	1.22%	Perf Quarter	-30.36%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-21.52%	Short Ratio	0.51	Perf Half Y	98.45%
Book/sh	2.50	P/B	3.59	EPS next Y	-	ROA	-114.02%	Short Interest	0.04M	Perf Year	37.16%
Cash/sh	0.16	P/C	57.81	EPS next 5Y	-	ROE	-226.63%	52W Range	2.31 - 13.70	Perf YTD	63.09%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-322.46%	ROI	-199.44%	52W High	-34.53%	Beta	-0.63
Dividend TTM	-	Quick Ratio	0.23	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	288.31%	ATR (14)	1.15
Dividend Ex-Date	-	Current Ratio	0.23	EPS Y/Y TTM	68.19%	Oper. Margin	-	RSI (14)	44.80	Volatility	24.57% 9.92%
Employees	7	Debt/Eq	0.26	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	80.00
Option/Short	No / Yes	LT Debt/Eq	0.03	EPS Q/Q	33.06%	Payout	-	Rel Volume	2.79	Prev Close	7.70
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	70.50K	Price	8.97
SMA20	-8.42%	SMA50	-11.93%	SMA200	38.54%	Trades		Volume	196,955	Change	16.49%

Apr-25-25 08:33AM	Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement (GlobeNewswire) -38.25%
Apr-17-25 08:38AM	COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology (GlobeNewswire) +7.82%
Apr-15-25 08:33AM	NUBURU Announces Strategic Corporate Update Focused on Defense & Security, Advanced Technologies, and Growth Initiatives (Business Wire)
Mar-11-25 08:34AM	Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline (GlobeNewswire)
Mar-07-25 08:37AM	COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan (GlobeNewswire)
08:00AM	Loading…
Mar-06-25 08:00AM	NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan (Business Wire) -5.09%
Feb-20-25 09:00AM	COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network (GlobeNewswire) -16.44%
07:27AM	COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing (GlobeNewswire)
Feb-19-25 04:00PM	COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing (GlobeNewswire)
Feb-13-25 08:39AM	COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups (GlobeNewswire)
Feb-06-25 08:08AM	COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration (PR Newswire)
Jan-30-25 08:27AM	Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation (PR Newswire)
Jan-23-25 08:09AM	Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation (PR Newswire) -9.81%
Jan-22-25 08:00AM	Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2) (PR Newswire) +13.56%
Jan-07-25 08:00AM	Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform (PR Newswire)
08:15AM	Loading…
Dec-27-24 08:15AM	Coeptis Therapeutics Announces Reverse Stock Split (PR Newswire) -13.65%
Dec-26-24 08:15AM	Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies (PR Newswire) +48.59%
Dec-12-24 08:00AM	Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies (PR Newswire)
Dec-03-24 08:15AM	Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries (PR Newswire) +17.51%
Nov-07-24 08:07AM	Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development (PR Newswire)
Oct-24-24 08:07AM	Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use (PR Newswire) -6.64%
Oct-15-24 08:07AM	Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy (PR Newswire)
Sep-19-24 07:07AM	Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing (PR Newswire) +5.47%
Sep-05-24 08:07AM	Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders (PR Newswire) -5.66%
Aug-16-24 08:52PM	COEP Stock Earnings: Coeptis Therapeutics Reported Results for Q2 2024 (InvestorPlace) +5.15%
Jun-20-24 08:47AM	Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering (PR Newswire) -8.81%
May-30-24 08:47AM	Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting (PR Newswire)
May-13-24 09:53AM	COEP Stock Earnings: Coeptis Therapeutics Reported Results for Q1 2024 (InvestorPlace) -7.07%
May-08-24 08:47AM	Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 (PR Newswire)
May-02-24 08:47AM	Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting (PR Newswire) +8.77%
08:47AM	Loading…
Apr-02-24 08:47AM	Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award (PR Newswire) +6.68%
Feb-26-24 09:00AM	Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK (PR Newswire) +9.89%
Feb-07-24 07:30AM	Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections (PR Newswire)
Jan-04-24 07:30AM	Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 (PR Newswire) -10.71%
Dec-06-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now (GlobeNewswire) -7.02%
Dec-05-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now (GlobeNewswire) -5.00%
Dec-04-23 07:30AM	Coeptis Therapeutics to Present at the Emerging Growth Conference (PR Newswire)
Oct-31-23 09:01AM	Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023 (PR Newswire) -9.74%
07:00AM	Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now (GlobeNewswire)
Oct-24-23 08:30AM	Coeptis Therapeutics Announces $2 Million Private Placement (PR Newswire)
Oct-11-23 07:30AM	Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology (PR Newswire)
Oct-09-23 09:15AM	Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies (PR Newswire)
Oct-04-23 07:30AM	Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting (PR Newswire)
Oct-03-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now (GlobeNewswire)
Sep-27-23 07:30AM	Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa (PR Newswire) +10.31%
Sep-14-23 07:30AM	Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection (PR Newswire)
Sep-11-23 07:30AM	Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment (PR Newswire) -5.29%
Aug-30-23 01:00PM	Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer (PR Newswire)
Aug-17-23 07:30AM	Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics (PR Newswire)
Aug-01-23 08:00AM	Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic (PR Newswire)
Jun-16-23 04:00PM	Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering (PR Newswire) -5.59%
Jun-14-23 09:28AM	Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering (PR Newswire) +6.06%
Jun-09-23 07:00AM	Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market (PR Newswire)
May-17-23 08:30AM	Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer (PR Newswire)
May-10-23 03:00PM	Coeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications (PR Newswire)
Apr-18-23 07:30AM	Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics (PR Newswire) +9.16%
Mar-29-23 09:45AM	Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies (PR Newswire)
Mar-21-23 07:00AM	Coeptis Therapeutics' SNAP-CAR Technology Platform Highlighted in Peer-Reviewed Article in Translational Medicine (PR Newswire)
Feb-07-23 08:00AM	Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short Selling (PR Newswire)
Jan-31-23 07:30AM	Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program (PR Newswire) +12.73%
Nov-22-22 07:00AM	Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development Program (PR Newswire) -6.17%
Nov-15-22 07:00AM	Coeptis Therapeutics Holdings to Ring the Nasdaq Stock Market Opening Bell (PR Newswire)
Nov-08-22 07:00AM	Coeptis Therapeutics' Scientific Advisory Board Members Featured on "Biology of Natural Killer (NK) Cells" Podcast (PR Newswire) -17.13%
Nov-02-22 07:00AM	Coeptis Therapeutics Holdings Expands Board of Directors with New Appointments (PR Newswire) -8.81%
Sep-21-22 07:00AM	Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a "Multi-Antigen" CAR T Technology (PR Newswire)
May-17-22 07:00AM	Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors (PR Newswire)
Apr-19-22 07:00AM	Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement (PR Newswire)
Apr-13-22 04:05PM	Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod (GlobeNewswire)
07:00AM	Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma (PR Newswire)
Jan-20-22 08:00AM	Coeptis Therapeutics Establishes Scientific Advisory Board to Advance Cell Therapy Product Development (PR Newswire)

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. The firm's products include CD38-GEAR-NK, CD38-Diagnostic and GEAR-NK Product. The company was founded in 2017 and is headquartered in Wexford, PA.

UPXI

Upexi Inc

COEP

Coeptis Therapeutics Holdings Inc

Upgrade your FINVIZ experience